Skip to main content

Advertisement

Table 2 The association between LINE-1 methylation status and clinical variables of the study population (stage III and high-risk stage II CRCs)

From: Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Parameters LINE-1 methylation levels (low vs. high)a
Cancer sample (n = 336) Normal lymph node sample (n = 336)
OR (95 % C.I.) P b OR (95 % C.I.) P b
Gender
 (Male vs. female) 1.49 (0.921–2.406) 0.104 1.06 (0.670–1.677) 0.803
Age
 (≥60 years vs. <60 years) 1.20 (0.752–1.899) 0.450 0.95 (0.611–1.480) 0.823
BMI
 (Overweight vs. normal) 1.24 (0.775–1.996) 0.366 1.76 (1.118–2.765) 0.015
Tumor location
 (Distal vs. proximal) 0.81 (0.474–1.373) 0.429 1.26 (0.762–2.079) 0.370
Pathology
 (Mucinous vs. non-mucinous) 0.83 (0.196–3.521) 0.802 1.44 (0.349–5.926) 0.616
Differentiation
 (High grade vs. low grade) 0.37 (0.111–1.211) 0.100 0.68 (0.213–2.173) 0.515
T stage
 (T4 vs. T1, 2, 3) 0.81 (0.403–1.629) 0.555 0.68 (0.347–1.324) 0.255
N stage
 (N2 vs. N 0, 1) 1.24 (0.715–2.156) 0.443 1.15 (0.681–1.938) 0.602
Microsatellite status
 (MSI-H vs. MSS + MSI-L) 0.33 (0.106–1.008) 0.052 0.76 (0.283–2.026) 0.580
Performance status
 (PS ≥1 vs. PS = 0) 2.56 (1.601–4.102) <0.001 1.12 (0.718–1.752) 0.615
  1. BMI body mass index, MSI-H microsatellite instability, MSS microsatellite stable, MSI-L microsatellite instability-low, PS performance status
  2. aCut-off points of LINE-1 methylation proportion were 54.62 % in cancer tissue samples and 77.00 % in normal lymph node samples
  3. bUnconditional logistic regression, adjusted for other selected covariates